SCLXW
Scilex Holding Company
Price Chart
Latest Quote
$0.17
+0.00 (+0.00%)
Current Price
| Previous Close | $0.17 |
| Open | $0.17 |
| Day High | $0.17 |
| Day Low | $0.15 |
| Volume | 81 |
Stock Information
| Total Debt | $106.36M |
| Cash Equivalents | $3.36M |
| Revenue | $33.86M |
| Net Income | $-419.68M |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Sales | $33.86M |
| Income | $-419.68M |
| Book/sh | $-29.54 |
| Employees | 34 |
Financial Ratios
| Quick Ratio | 0.07 |
| Current Ratio | 0.08 |
Returns & Margins
| ROA | -92.78% |
| Gross Margin | 59.65% |
| Operating Margin | -373.49% |
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
| P/B | -0.01 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.14 |
| SMA50 | $0.14 |
| RSI | nan |
| Shares Float | 5.19M |
| Volatility | 1.71 |
Performance History
| Week | +0.00% |
| Month | +0.00% |
| Quarter | +0.00% |
| YTD | -8.72% |
| 10 Years | -8.72% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-12 | $0.14 | 0 |
| 2026-06-11 | $0.14 | 0 |
| 2026-06-10 | $0.14 | 0 |
| 2026-06-09 | $0.14 | 0 |
| 2026-06-08 | $0.14 | 0 |
| 2026-06-05 | $0.14 | 0 |
| 2026-06-04 | $0.14 | 0 |
| 2026-06-03 | $0.14 | 0 |
| 2026-06-02 | $0.14 | 0 |
| 2026-06-01 | $0.14 | 0 |
| 2026-05-29 | $0.14 | 0 |
| 2026-05-28 | $0.14 | 0 |
| 2026-05-27 | $0.14 | 0 |
| 2026-05-26 | $0.14 | 0 |
| 2026-05-22 | $0.14 | 0 |
| 2026-05-21 | $0.14 | 0 |
| 2026-05-20 | $0.14 | 0 |
| 2026-05-19 | $0.14 | 0 |
About Scilex Holding Company
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA; and Tulex Master, which develops, tests, and manufactures clinical supplies of SP-104. Scilex Holding Company is based in Palo Alto, California.
đ° Latest News
Wellgistics Health, Datavault AI Agree to Form DelivMeds AI
MT Newswires âĸ 2026-05-20T14:27:01ZDatavault AI Signs Binding Term Sheet for $120 Million Cash Contribution From Scilex
MT Newswires âĸ 2026-04-27T13:55:27ZScilex Holding Company (NASDAQ:SCLX) Is Expected To Breakeven In The Near Future
Simply Wall St. âĸ 2025-10-28T16:05:32Z
This Penny Stock Is Surging on Supercomputer and Bitcoin Plans. Should You Buy It Now?
Barchart âĸ 2025-09-26T17:52:25Z
Datavault AI (DVLT) Touches $1 Level Anew After 4 Months on New $150-Million Investment
Insider Monkey âĸ 2025-09-26T12:07:21Z
Sector Update: Health Care Stocks Climb Late Afternoon
MT Newswires âĸ 2025-08-13T19:56:28ZSector Update: Health Care Stocks Gain Wednesday Afternoon
MT Newswires âĸ 2025-08-13T18:01:21Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $10,340,000 | $16,674,000 | $15,641,000 | $10,758,000 |
| Cost Of Revenue | $10,599,000 | $16,689,000 | $15,681,000 | $10,797,000 |
| Total Revenue | $30,253,000 | $56,590,000 | $46,743,000 | $38,034,000 |
| Operating Revenue | $30,253,000 | $56,590,000 | $46,743,000 | $38,034,000 |
| Expenses | ||||
| Interest Expense | $11,459,000 | $1,963,000 | $1,068,000 | $9,604,000 |
| Total Expenses | $302,557,000 | $149,377,000 | $152,174,000 | $88,668,000 |
| Other Income Expense | $-90,264,000 | $21,942,000 | $-7,819,000 | $36,878,000 |
| Other Non Operating Income Expenses | $-25,351,000 | $-4,782,000 | $-7,189,000 | - |
| Net Non Operating Interest Income Expense | $-11,459,000 | $-1,963,000 | $-1,068,000 | $-9,604,000 |
| Interest Expense Non Operating | $11,459,000 | $1,963,000 | $1,068,000 | $9,604,000 |
| Operating Expense | $291,958,000 | $132,688,000 | $136,493,000 | $77,871,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-358,734,000 | $-72,807,000 | $-114,331,000 | $-23,364,000 |
| Net Interest Income | $-11,459,000 | $-1,963,000 | $-1,068,000 | $-9,604,000 |
| Normalized Income | $-234,404,000 | $-99,530,633 | $-113,833,300 | $-52,497,620 |
| Net Income From Continuing And Discontinued Operation | $-358,734,000 | $-72,807,000 | $-114,331,000 | $-23,364,000 |
| Total Operating Income As Reported | $-346,007,000 | $-83,396,000 | $-105,431,000 | $-50,634,000 |
| Net Income Common Stockholders | $-402,487,000 | $-72,807,000 | $-166,976,000 | $-23,364,000 |
| Net Income | $-358,734,000 | $-72,807,000 | $-114,331,000 | $-23,364,000 |
| Net Income Including Noncontrolling Interests | $-374,053,000 | $-72,807,000 | $-114,331,000 | $-23,364,000 |
| Net Income Continuous Operations | $-374,053,000 | $-72,807,000 | $-114,331,000 | $-23,364,000 |
| Pretax Income | $-374,027,000 | $-72,808,000 | $-114,318,000 | $-23,360,000 |
| Special Income Charges | $-81,054,000 | $9,391,000 | $0 | $28,634,000 |
| Earnings From Equity Interest | $59,417,000 | $0 | - | - |
| Operating Income | $-272,304,000 | $-92,787,000 | $-105,431,000 | $-50,634,000 |
| Depreciation Amortization Depletion Income Statement | $4,364,000 | $4,031,000 | $4,106,000 | $3,922,000 |
| Depreciation And Amortization In Income Statement | $4,364,000 | $4,031,000 | $4,106,000 | $3,922,000 |
| Amortization Of Intangibles Income Statement | $4,364,000 | $4,031,000 | $4,106,000 | $3,922,000 |
| Gross Profit | $19,654,000 | $39,901,000 | $31,062,000 | $27,237,000 |
| Interest Income | - | - | - | - |
| Interest Income Non Operating | - | - | - | - |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $367 | $-132,300 | $7,744,380 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-233,615,000 | $-93,523,000 | $-108,474,000 | $-46,673,000 |
| Total Unusual Items | $-124,330,000 | $26,724,000 | $-630,000 | $36,878,000 |
| Total Unusual Items Excluding Goodwill | $-124,330,000 | $26,724,000 | $-630,000 | $36,878,000 |
| Reconciled Depreciation | $4,623,000 | $4,046,000 | $4,146,000 | $3,961,000 |
| EBITDA (Bullshit earnings) | $-357,945,000 | $-66,799,000 | $-109,104,000 | $-9,795,000 |
| EBIT | $-362,568,000 | $-70,845,000 | $-113,250,000 | $-13,756,000 |
| Diluted NI Availto Com Stockholders | $-402,487,000 | $-72,807,000 | $-166,976,000 | $-23,364,000 |
| Otherunder Preferred Stock Dividend | $43,753,000 | $0 | - | $0 |
| Minority Interests | $15,319,000 | $0 | - | - |
| Tax Provision | $26,000 | $-1,000 | $13,000 | $4,000 |
| Other Special Charges | $7,696,000 | $-9,391,000 | - | $-28,634,000 |
| Impairment Of Capital Assets | $73,358,000 | $0 | - | - |
| Gain On Sale Of Security | $-43,276,000 | $17,333,000 | $-630,000 | $8,244,000 |
| Amortization | $4,364,000 | $4,031,000 | $4,106,000 | $3,922,000 |
| Research And Development | $20,710,000 | $9,641,000 | $12,746,000 | $9,054,000 |
| Selling General And Administration | $266,884,000 | $119,016,000 | $119,641,000 | $64,895,000 |
| Preferred Stock Dividends | - | - | $52,645,000 | - |
Fetched: 2026-06-16
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-345,063,000 | $-238,577,000 | $-222,904,000 | $-17,833,000 |
| Total Assets | $364,981,000 | $92,953,000 | $101,309,000 | $86,527,000 |
| Total Non Current Assets | $326,624,000 | $51,406,000 | $54,528,000 | $56,919,000 |
| Other Non Current Assets | $32,886,000 | $119,000 | $897,000 | $944,000 |
| Goodwill And Other Intangible Assets | $137,281,000 | $45,934,000 | $49,966,000 | $54,072,000 |
| Other Intangible Assets | $123,800,000 | $32,453,000 | $36,485,000 | $40,591,000 |
| Current Assets | $38,358,000 | $41,547,000 | $46,781,000 | $29,608,000 |
| Other Current Assets | $7,344,000 | $9,397,000 | $4,049,000 | $4,810,000 |
| Inventory | $4,789,000 | $2,436,000 | $4,214,000 | $1,378,000 |
| Receivables | $15,244,000 | $26,442,000 | $34,597,000 | $21,236,000 |
| Accounts Receivable | $15,244,000 | $26,442,000 | $34,597,000 | $21,236,000 |
| Cash Cash Equivalents And Short Term Investments | $10,981,000 | $3,272,000 | $3,921,000 | $2,184,000 |
| Cash And Cash Equivalents | $4,955,000 | $3,272,000 | $3,921,000 | $2,184,000 |
| Non Current Prepaid Assets | - | - | - | - |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $104,304,000 | $32,449,000 | $121,546,000 | - |
| Total Debt | $124,143,000 | $37,958,000 | $128,463,000 | $1,410,000 |
| Long Term Debt And Capital Lease Obligation | $35,631,000 | $2,368,000 | $19,275,000 | $665,000 |
| Long Term Debt | $22,480,000 | $845,000 | $17,038,000 | - |
| Current Debt And Capital Lease Obligation | $88,512,000 | $35,590,000 | $109,188,000 | $745,000 |
| Current Debt | $86,779,000 | $34,876,000 | $108,429,000 | - |
| Other Current Borrowings | $83,262,000 | $34,876,000 | $108,429,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $576,734,000 | $285,596,000 | $274,247,000 | $50,288,000 |
| Total Non Current Liabilities Net Minority Interest | $93,082,000 | $25,961,000 | $23,867,000 | $5,446,000 |
| Other Non Current Liabilities | $175,000 | $157,000 | $179,000 | $163,000 |
| Derivative Product Liabilities | $50,599,000 | $18,303,000 | $1,518,000 | $1,231,000 |
| Non Current Deferred Liabilities | $6,677,000 | $5,133,000 | $2,895,000 | $3,387,000 |
| Current Liabilities | $483,652,000 | $259,635,000 | $250,380,000 | $44,842,000 |
| Other Current Liabilities | $3,263,000 | - | - | - |
| Current Deferred Liabilities | $4,171,000 | $4,562,000 | $491,000 | $264,000 |
| Current Notes Payable | $3,517,000 | $0 | - | - |
| Payables And Accrued Expenses | $387,706,000 | $219,483,000 | $140,701,000 | $43,833,000 |
| Interest Payable | $6,862,000 | $0 | - | - |
| Payables | $86,316,000 | $53,496,000 | $42,406,000 | $8,450,000 |
| Total Tax Payable | $50,000 | $876,000 | $1,452,000 | $0 |
| Accounts Payable | $86,266,000 | $52,620,000 | $40,954,000 | $8,450,000 |
| Equity | ||||
| Common Stock Equity | $-207,783,000 | $-192,643,000 | $-172,938,000 | $36,236,000 |
| Preferred Stock Equity | $1,000 | $1,000 | - | $3,000 |
| Total Equity Gross Minority Interest | $-211,753,000 | $-192,643,000 | $-172,938,000 | $36,239,000 |
| Stockholders Equity | $-207,782,000 | $-192,643,000 | $-172,938,000 | $36,239,000 |
| Gains Losses Not Affecting Retained Earnings | $-5,803,000 | $6,317,000 | $0 | - |
| Other Equity Adjustments | $-5,803,000 | $6,317,000 | - | - |
| Retained Earnings | $-921,786,000 | $-563,052,000 | $-490,245,000 | $-375,914,000 |
| Long Term Equity Investment | $127,040,000 | - | - | - |
| Other | ||||
| Treasury Shares Number | $1,458,263 | $1,716,245 | $1,716,245 | - |
| Ordinary Shares Number | $7,033,004 | $5,235,551 | $2,857,590 | $4,038,538 |
| Share Issued | $8,491,267 | $6,951,796 | $4,573,835 | $4,038,538 |
| Tangible Book Value | $-345,064,000 | $-238,577,000 | $-222,904,000 | $-17,836,000 |
| Invested Capital | $-98,524,000 | $-156,922,000 | $-47,471,000 | $36,236,000 |
| Working Capital | $-445,294,000 | $-218,088,000 | $-203,599,000 | $-15,234,000 |
| Capital Lease Obligations | $14,884,000 | $2,237,000 | $2,996,000 | $1,410,000 |
| Total Capitalization | $-185,302,000 | $-191,798,000 | $-155,900,000 | $36,239,000 |
| Minority Interest | $-3,971,000 | $0 | - | - |
| Treasury Stock | $76,915,000 | $90,522,000 | $90,522,000 | $0 |
| Additional Paid In Capital | $796,721,000 | $454,614,000 | $407,813,000 | $412,136,000 |
| Capital Stock | $1,000 | $0 | $16,000 | $17,000 |
| Common Stock | $0 | $0 | $16,000 | $14,000 |
| Preferred Stock | $1,000 | $0 | $0 | $3,000 |
| Non Current Deferred Revenue | $4,636,000 | $2,685,000 | $0 | - |
| Long Term Capital Lease Obligation | $13,151,000 | $1,523,000 | $2,237,000 | $665,000 |
| Current Deferred Revenue | $3,764,000 | $4,115,000 | $0 | - |
| Current Capital Lease Obligation | $1,733,000 | $714,000 | $759,000 | $745,000 |
| Current Accrued Expenses | $301,390,000 | $165,987,000 | $98,295,000 | $35,383,000 |
| Investments And Advances | $128,040,000 | $2,420,000 | $0 | - |
| Other Investments | $1,000,000 | $2,420,000 | - | - |
| Goodwill | $13,481,000 | $13,481,000 | $13,481,000 | $13,481,000 |
| Net PPE | $28,417,000 | $2,933,000 | $3,665,000 | $1,903,000 |
| Accumulated Depreciation | $-321,000 | $-64,000 | $-58,000 | $-167,000 |
| Gross PPE | $28,738,000 | $2,997,000 | $3,723,000 | $2,070,000 |
| Leases | $3,746,000 | $50,000 | $50,000 | $55,000 |
| Construction In Progress | $909,000 | $689,000 | $689,000 | $689,000 |
| Other Properties | $14,818,000 | $2,225,000 | $2,943,000 | $1,131,000 |
| Machinery Furniture Equipment | $8,406,000 | $33,000 | $41,000 | $195,000 |
| Land And Improvements | $859,000 | $0 | - | - |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $6,026,000 | - | - | - |
| Dueto Related Parties Current | - | - | - | $0 |
Fetched: 2026-06-16
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $3,083,000 | $18,749,000 | $-21,037,000 | $-23,325,000 |
| Operating Activities | ||||
| Operating Cash Flow | $3,816,000 | $19,349,000 | $-20,707,000 | $-21,258,000 |
| Cash Flow From Continuing Operating Activities | $3,816,000 | $19,349,000 | $-20,707,000 | $-21,258,000 |
| Operating Gains Losses | $-15,101,000 | $-17,378,000 | $512,000 | $-35,247,000 |
| Investing Activities | ||||
| Capital Expenditure | $-733,000 | $-600,000 | $-330,000 | $-2,067,000 |
| Investing Cash Flow | $4,084,000 | $-2,675,000 | $-330,000 | $-2,067,000 |
| Cash Flow From Continuing Investing Activities | $4,084,000 | $-2,675,000 | $-330,000 | $-2,067,000 |
| Net Other Investing Changes | $-19,269,000 | - | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $44,638,000 | $35,458,000 | $0 |
| Financing Cash Flow | $-5,461,000 | $-18,131,000 | $23,582,000 | $21,171,000 |
| Cash Flow From Continuing Financing Activities | $-5,461,000 | $-18,131,000 | $23,582,000 | $21,171,000 |
| Net Other Financing Charges | $-9,517,000 | $-371,000 | $-3,739,000 | $52,326,000 |
| Net Common Stock Issuance | $0 | $44,638,000 | $25,458,000 | $0 |
| Common Stock Issuance | $0 | $44,638,000 | $35,458,000 | $0 |
| Repurchase Of Capital Stock | - | $0 | $-10,000,000 | $0 |
| Other | ||||
| Repayment Of Debt | $-21,090,000 | $-184,649,000 | $-109,626,000 | $-103,608,000 |
| Issuance Of Debt | $21,528,000 | $120,438,000 | $110,354,000 | $72,357,000 |
| Interest Paid Supplemental Data | $935,000 | $1,561,000 | $1,426,000 | $0 |
| End Cash Position | $4,955,000 | $3,272,000 | $4,729,000 | $2,184,000 |
| Beginning Cash Position | $3,272,000 | $4,729,000 | $2,184,000 | $4,338,000 |
| Effect Of Exchange Rate Changes | $-756,000 | $0 | - | - |
| Changes In Cash | $2,439,000 | $-1,457,000 | $2,545,000 | $-2,154,000 |
| Proceeds From Stock Option Exercised | $3,618,000 | $1,813,000 | $1,135,000 | $96,000 |
| Net Issuance Payments Of Debt | $438,000 | $-64,211,000 | $728,000 | $-31,251,000 |
| Net Long Term Debt Issuance | $438,000 | $-64,211,000 | $728,000 | $-31,251,000 |
| Long Term Debt Payments | $-21,090,000 | $-184,649,000 | $-109,626,000 | $-103,608,000 |
| Long Term Debt Issuance | $21,528,000 | $120,438,000 | $110,354,000 | $72,357,000 |
| Net Investment Purchase And Sale | $-17,037,000 | $-2,075,000 | $0 | - |
| Purchase Of Investment | $-17,037,000 | $-2,075,000 | $0 | - |
| Net Business Purchase And Sale | $41,123,000 | $0 | - | - |
| Sale Of Business | $41,123,000 | $0 | - | - |
| Net Intangibles Purchase And Sale | $-600,000 | $-600,000 | $-300,000 | $-2,060,000 |
| Purchase Of Intangibles | $-600,000 | $-600,000 | $-300,000 | $-2,060,000 |
| Net PPE Purchase And Sale | $-133,000 | $0 | $-30,000 | $-7,000 |
| Purchase Of PPE | $-133,000 | $0 | $-30,000 | $-7,000 |
| Change In Working Capital | $113,967,000 | $64,839,000 | $65,802,000 | $45,668,000 |
| Change In Other Current Liabilities | $-832,000 | $-782,000 | $-695,000 | $-229,000 |
| Change In Other Current Assets | $-3,000 | $-30,000 | $855,000 | $350,000 |
| Change In Payables And Accrued Expense | $95,866,000 | $70,935,000 | $82,282,000 | $53,960,000 |
| Change In Accrued Expense | $82,745,000 | $63,516,000 | $62,402,000 | $21,029,000 |
| Change In Payable | $13,121,000 | $7,419,000 | $19,880,000 | $32,931,000 |
| Change In Account Payable | $13,121,000 | $7,419,000 | $19,880,000 | $2,806,000 |
| Change In Prepaid Assets | $3,300,000 | $-479,000 | $-441,000 | $-2,629,000 |
| Change In Inventory | $1,799,000 | $1,462,000 | $-2,838,000 | $1,184,000 |
| Change In Receivables | $13,837,000 | $-6,267,000 | $-13,361,000 | $-6,968,000 |
| Changes In Account Receivables | $13,837,000 | $-6,267,000 | $-13,361,000 | $-6,968,000 |
| Other Non Cash Items | $188,222,000 | $6,477,000 | $8,568,000 | $-17,556,000 |
| Stock Based Compensation | $15,492,000 | $15,689,000 | $14,596,000 | $5,280,000 |
| Unrealized Gain Loss On Investment Securities | $-2,692,000 | $0 | - | - |
| Provisionand Write Offof Assets | $0 | $18,483,000 | $0 | - |
| Asset Impairment Charge | $73,358,000 | $0 | - | - |
| Depreciation Amortization Depletion | $4,623,000 | $4,046,000 | $4,146,000 | $3,961,000 |
| Depreciation And Amortization | $4,623,000 | $4,046,000 | $4,146,000 | $3,961,000 |
| Earnings Losses From Equity Investments | $-54,759,000 | $0 | - | - |
| Gain Loss On Investment Securities | $44,315,000 | $-17,378,000 | $512,000 | $-6,613,000 |
| Gain Loss On Sale Of Business | $-4,657,000 | $0 | - | - |
| Net Income From Continuing Operations | $-374,053,000 | $-72,807,000 | $-114,331,000 | $-23,364,000 |
| Common Stock Payments | - | $0 | $-10,000,000 | $0 |
| Net Short Term Debt Issuance | - | - | $24,000,000 | $0 |
| Short Term Debt Payments | - | - | $-84,626,000 | $0 |
| Short Term Debt Issuance | - | - | $24,000,000 | $0 |
| Purchase Of Business | - | - | - | - |
Fetched: 2026-06-16